论文信息 - Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - 字舞流文

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

J. Kleijnen | G. Worthy | M. Joore | S. Grimm | N. Armstrong | R. Wolff | L. Stirk | A. V. van Asselt | T. Buksnys | W. Witlox | A. Chalker | Sabine E. Grimm | Willem J. A. Witlox | Titas Buksnys | Antoinette D. I. van Asselt

[1] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[2] M. Oudkerk,et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[4] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .

[5] D. de Ruysscher,et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[6] N. Latimer. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making.

[7] A. Krishan,et al. Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer , 2016 .

[8] D. Quinton,et al. Unit Costs of Health and Social Care 2004 , 2004 .